PubRank

Bo Svennerholm

Author PubWeight™ 22.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010 3.46
2 The antibody response to pandemic H1N1 2009 influenza vaccine in adult organ transplant patients. Transpl Int 2011 1.43
3 Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 2010 1.15
4 Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Scand J Infect Dis 2004 1.06
5 Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002 1.04
6 Treatment of HIV infection: Swedish recommendations 2009. Scand J Infect Dis 2009 1.03
7 Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther 2006 0.97
8 Monoclonal antibodies and human sera directed to the secreted glycoprotein G of herpes simplex virus type 2 recognize type-specific antigenic determinants. J Gen Virol 2002 0.93
9 Secreted portion of glycoprotein g of herpes simplex virus type 2 is a novel antigen for type-discriminating serology. J Clin Microbiol 2003 0.92
10 Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy. Scand J Infect Dis 2012 0.89
11 Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)). Int J Biochem Cell Biol 2004 0.89
12 Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Scand J Infect Dis 2007 0.88
13 No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide. Antiviral Res 2004 0.87
14 Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide. Antimicrob Agents Chemother 2005 0.87
15 Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Scand J Infect Dis 2014 0.86
16 Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity. Antimicrob Agents Chemother 2008 0.84
17 Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells. Antiviral Res 2004 0.81
18 Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates. AIDS Res Hum Retroviruses 2009 0.81
19 Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV. AIDS Res Ther 2011 0.78
20 Application of a colorimetric chain-termination assay for characterization of reverse transcriptase from 3'-azido-2',3'-deoxythymidine-resistant HIV isolates. Biotechnol Appl Biochem 2002 0.78
21 Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013. Scand J Infect Dis 2014 0.77
22 Cerebrospinal fluid viral load and intrathecal immune activation in individuals infected with different HIV-1 genetic subtypes. PLoS One 2008 0.77
23 Antibody persistence 1 year after pandemic H1N1 2009 influenza vaccination and immunogenicity of subsequent seasonal influenza vaccine among adult organ transplant patients. Transpl Int 2013 0.75
24 Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection. AIDS Res Hum Retroviruses 2004 0.75